CN113881629A - 一种体外高效扩增nk细胞的培养基及培养方法 - Google Patents
一种体外高效扩增nk细胞的培养基及培养方法 Download PDFInfo
- Publication number
- CN113881629A CN113881629A CN202010630415.2A CN202010630415A CN113881629A CN 113881629 A CN113881629 A CN 113881629A CN 202010630415 A CN202010630415 A CN 202010630415A CN 113881629 A CN113881629 A CN 113881629A
- Authority
- CN
- China
- Prior art keywords
- cells
- culture medium
- percent
- vitro
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 76
- 239000001963 growth medium Substances 0.000 title claims abstract description 30
- 238000000338 in vitro Methods 0.000 title claims abstract description 21
- 238000012136 culture method Methods 0.000 title abstract description 7
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims abstract description 28
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 15
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 15
- 229940016667 resveratrol Drugs 0.000 claims abstract description 15
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 15
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 14
- 229930182816 L-glutamine Natural products 0.000 claims abstract description 14
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 14
- 229940054269 sodium pyruvate Drugs 0.000 claims abstract description 14
- 239000000654 additive Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000006143 cell culture medium Substances 0.000 claims abstract description 12
- 150000001413 amino acids Chemical class 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 45
- 238000004113 cell culture Methods 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 10
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims description 8
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 8
- 102000056003 human IL15 Human genes 0.000 claims description 8
- 239000002609 medium Substances 0.000 claims description 8
- 210000005087 mononuclear cell Anatomy 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 3
- 235000020776 essential amino acid Nutrition 0.000 claims description 3
- 239000003797 essential amino acid Substances 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 3
- 230000036436 anti-hiv Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000007640 basal medium Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 230000001502 supplementing effect Effects 0.000 claims 1
- 230000002147 killing effect Effects 0.000 abstract description 12
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 239000011324 bead Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 231100000225 lethality Toxicity 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract 1
- 210000002993 trophoblast Anatomy 0.000 abstract 1
- 239000012636 effector Substances 0.000 description 9
- 108010087230 Sincalide Proteins 0.000 description 7
- 238000010609 cell counting kit-8 assay Methods 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 7
- 238000000926 separation method Methods 0.000 description 6
- 230000003321 amplification Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 102000052620 human IL10 Human genes 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开提供了一种体外高效扩增NK细胞的培养基和培养方法,所述培养基包括基础培养基和添加物,所述基础培养基为X‑VIVO 15,添加物各组分及浓度为:2.0%‑10.0%自体血浆,0.5‑2.0 uM白藜芦醇,1.0‑10.0 mM烟酰胺,1%丙酮酸钠,1%非必需氨基酸,1%L‑谷氨酰胺。本发明还公开了一种体外扩增NK细胞的方法,不使用滋养层细胞或磁珠分选纯化,操作简便,可扩增出数量大,活性高,对肿瘤细胞杀伤力强的NK细胞。本发明提供的NK细胞培养基培养NK细胞两周后,增殖倍数翻了近150倍;对1301的杀伤活性在25:1的效靶比时达到了84.21%。
Description
技术领域
本发明涉及细胞培养技术领域,涉及一种体外高效扩增NK细胞的培养基及培养方法。
背景技术
自然杀伤细胞(nature killer cell,NK)是独立于T、B细胞的第三类淋巴细胞亚群,是机体内重要的免疫细胞,具有抗肿瘤、抗病毒感染和免疫调节功能,而且在某些情况下参与超敏反应和自身免疫性疾病的发生。NK细胞是机体先天获得性免疫系统最重要的组成细胞之一,无需预先致敏就可以杀伤某些血液肿瘤和异质细胞群,可在免疫应答早期发挥作用;同时NK细胞可释放穿孔素、颗粒酶B,穿孔素在靶细胞表面穿孔,使颗粒酶B进入靶细胞诱导凋亡程序,同时并分泌大量细胞因子作用于靶细胞,并可表达诱导细胞凋亡的蛋白和肿瘤坏死因子相关诱导配体,使靶细胞发生程序性凋亡。因此,NK细胞在免疫治疗中发挥重要作用。
目前,NK细胞体外培养方法主要包括:(1)免疫磁珠分选法。从外周血单个核细胞中分离少量NK细胞,经IL-2,IL-12,IL-15,IL-18等细胞因子组合,刺激外周血中单核细胞,获得纯度高,扩增力强,细胞毒性强的NK细胞。(2)NK细胞分离试剂盒法,通过商品化试剂盒进行NK细胞体外扩增。(3)采用照射致死的K562细胞或HFWT细胞刺激PBMC中的NK细胞扩增。然而免疫磁珠分离方法,生产成本较高,费时费力,不利于大规模生产;以肿瘤细胞作为饲养层细胞扩增NK细胞,操作复杂且异体细胞的安全性尚待探讨。虽然商品化培养基可体外扩增NK细胞,但是细胞的纯度和数量并不能满足临床需求。因此,开发一种高效、安全的NK细胞培养基及培养方法是NK细胞的临床研究与应用领域亟待解决的问题之一。
发明内容
本发明主要解决的技术问题是提供一种体外高效扩增NK细胞培养基及培养方法,可扩增出稳定增殖,活性高,对肿瘤细胞杀伤力强的NK细胞。
为解决上述技术问题,本发明采用如下技术方案:
本发明提供一种体外高效扩增NK细胞的培养基,包括基础培养基和添加物,添加物及各组分浓度为:2.0-10.0%自体血浆,0.5-2.0 uM白藜芦醇,1.0-10.0 mM烟酰胺,1%丙酮酸钠,1% 非必需氨基酸,1% L-谷氨酰胺。
其中,基础培养基为X-VIVO 15培养基。
其中,添加物各组分及浓度:2.0-10.0%自体血浆,0.5-2.0 uM白藜芦醇,1.0-10.0mM烟酰胺,1%丙酮酸钠,1%非必需氨基酸,1% L-谷氨酰胺。
其中,添加物各组分及浓度为:10%自体血浆,1 uM白藜芦醇,5 mM烟酰胺,1%丙酮酸钠,1%非必需氨基酸,1% L-谷氨酰胺。
为解决上述技术问题,本发明提供一种体外扩增NK细胞的方法,包括以下步骤:
(1)培养瓶抗体包被:用PBS稀释anti-HER2 MAb至所需浓度,包被T-75细胞培养瓶,4℃过夜或37℃ 1 h;
(2)血液分离:采集外周血50 ml于肝素锂抗凝的采血管中,1000 g离心15 min,取上层血浆,56℃灭活30 min,放置室温,400 g离心20 min分装,4℃保存;
(3)单个核细胞分离:Ficoll淋巴细胞分离液分离单个核细胞,PBS洗两遍,细胞计数,调整细胞密度为3-5×106个/ml;
(4)NK细胞体外诱导培养:细胞培养瓶中加入10%自体血浆,200 U/ml 重组人IL-2,1ng/ml重组人 IL-15,将细胞培养瓶置于37℃、5% CO2培养箱中培养3到4天。培养预定天数后,获得扩增的NK细胞。其中,NK细胞培养基包括基础培养基和添加物,添加物及各组分浓度为2.0-10.0%自体血浆,0.5-2.0 uM白藜芦醇,1.0-10.0 mM烟酰胺,1%丙酮酸钠,1% 非必需氨基酸,1% L-谷氨酰胺。
其中,初始悬于NK细胞培养基中NK细胞的密度为5×106个/20ml。
其中,anti-HER2 MAb浓度为10 ug/ml,重组人IL-2浓度为200 IU/ml,重组人IL-15浓度为1 ng/ml。
其中,基础培养基为X-VIVO 15。
其中,添加物及各组分浓度为10% 自体血浆,1 uM白藜芦醇,5 mM烟酰胺,1%丙酮酸钠,1%非必需氨基酸,1% L-谷氨酰胺。
其中,细胞培养为细胞培养瓶和透气细胞培养袋。
本发明的有益效果是:通过上述技术方案,本发明提供的NK细胞体外扩增培养基能够避免动物血清成分和异体细胞的添加,增加NK细胞在临床应用中的安全性。采用不同组分的培养基在细胞生产的特定阶段有针对性的进行培养,可更好的满足NK细胞在不同阶段的生长需求,更有效的扩增和活化NK细胞,且不改变细胞的表型并能增强细胞的杀伤活力。因此,可以将白藜芦醇,烟酰胺,丙酮酸钠,非必需氨基酸,L-谷氨酰胺添加到培养基中开发成细胞体外专用培养基。通过上述培养基体外扩增NK细胞,可扩增出数量大、活性高、杀伤性强的NK细胞。
附图说明
图1为实施例中分离培养的NK传代细胞的显微镜图(40×);
图2为实施例中分离培养的NK传代细胞的显微镜图(20×);
图3为实施例中分离培养的NK传代细胞的显微镜图(10×);
图4增殖曲线;
图5杀伤活性曲线。
具体实施方式
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。此外应理解,在阅读了本发明讲授的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
一、实验材料
淋巴细胞分离液购自北京索莱宝科技有限公司;X-VIVO 15,重组人IL-2,重组人IL-15均购自北京同立海源生物科技有限公司;FITC-Anti-CD3,PE-Anti-CD56,APC-Anti-CD16;FITC Mouse IgG1,κ Isotype Control;PE Mouse IgG1,κ Isotype Control;APC MouseIgG1,κ Isotype Control均购自美国BD公司;CCK-8东仁化学科技(上海)有限公司;烟酰胺,白藜芦醇购自山东优科生物科技有限公司,纯度≥95%。
二、实验方法
1.NK细胞的培养和表型鉴定
取健康成年志愿者外周静脉血,肝素锂抗凝后加入淋巴细胞分离液,1000 g离心15min,取上层血浆,56 ℃灭活30 min,放置室温,400 g离心20 min,分装,备用。将剩余血用PBS 1:1稀释,充分混匀,加入等体积的淋巴细胞分离液,1000 g离心30 min。吸取单个核细胞层。PBS洗涤3次,加入含有10%人自体血浆,1 uM白藜芦醇,5 mM烟酰胺,1%丙酮酸钠,1%非必需氨基酸,1% L-谷氨酰胺,200 IU/ml 重组人IL-2和1 ng/ml的重组人IL-15培养基中,于37℃、5% CO2培养箱中,每3天补加一次培养基。收集培养10 d的NK细胞,PBS洗涤三次后调整细胞密度为1×106/ml,在细胞悬液中加入FITC Mouse IgG1,κ Isotype Control;PEMouse IgG1,κ Isotype Control;APC Mouse IgG1,κ Isotype Control避光孵育20 min,PBS洗去未结合的抗体,流式细胞仪检测表型。
2.CCK-8法检测NK细胞增殖率
取培养10 d的NK细胞,用含有200 IU/ml 重组人IL-2,1ng/ml重组人IL-15和10% 自体血浆的培养基制成5×104/ml的细胞悬液,以5×103/ml接种于96孔板(即每孔100 ul),按如下分组更换培养基,每组3个复孔;
对照组:用含200 IU/ml 的重组人IL-2,1ng/ml重组人IL-15和10% 自体血浆的X-VIVO15培养基培养;
实验组:在对照组的基础上还含有1 uM白藜芦醇, 5 mM烟酰胺,1%丙酮酸钠,1%非必需氨基酸,1% L-谷氨酰胺;
另设只含有培养基不添加NK细胞的空白组;
在接种8 h后,每孔加入CCK-8液10 ul,继续培养4 h后弃去上清,在450 nm波长酶标仪上测定各孔吸光值(OD),求其平均值,扣除空白孔本底OD值按下式计算实验组细胞增殖率(%):
NK细胞增殖率(%)=(实验组OD值-对照组OD值)/对照组OD值×100%。
3.CCK-8法检测NK细胞对肿瘤细胞的杀伤活性
取培养10 d的NK细胞,用含有1 uM白藜芦醇,5 mM烟酰胺,1%丙酮酸钠,1%非必需氨基酸,1% L-谷氨酰胺的培养基(含有200 IU/ml 重组人IL-2,1 ng/ml 重组人IL-15和10%自体血浆的X-VIVO 15培养基)培养48 h,PBS充分洗涤3次,配成1×106/ml的细胞悬液,作为效应细胞;取对数生长期的1301人急性T淋巴细胞白血病细胞配成1×105/ml的细胞悬液,作为靶细胞。将效应细胞悬液和靶细胞悬液等体积(即效靶比10:1)接种于96孔板,同时设单独效应细胞孔,单独靶细胞孔,空白孔,每组3个复孔,于37℃,5% CO2培养箱中培养8 h。每孔加入CCK-8试剂10 ul,孵育0.5 h,在450 nm 波长酶标仪上测定各孔吸光值(OD),求其平均值,扣除本底孔OD值,按下式计算杀伤活性:
杀伤率(%)=[1-(实验组OD值-单独效应细胞OD值)/单独靶细胞OD值]×100%。
4.统计学方法
数据采用SPSS软件处理,以平均数±标准差表示,组间的表示采用独立样本t检验,P<0.05 为差异有统计学意义。
三、实验结果
1.NK细胞表型检测结果
收集培养10 d的NK细胞,PBS洗涤三次后调整细胞密度为1×106/ml,在细胞悬液中加入FITC Mouse IgG1,κ Isotype Control;PE Mouse IgG1,κ Isotype Control;APC MouseIgG1,κ Isotype Control避光孵育20 min,PBS洗去未结合的抗体,流式细胞仪检测表型,实验组的CD3-CD56+的NK细胞占81.45±1.38%,对照组的CD3-CD56+的NK细胞占52.13±1.02%,两组有显著性差异(P<0.05),结果如表1所示:
表1 实验组与常规组细胞纯度比较
2.NK细胞增殖率测定结果
将效应细胞和靶细胞按10:1、25:1和50:1的比例接种8 h后,每孔加入CCK-8液10 ul,继续培养0.5 h,在450 nm波长酶标仪上测定各孔吸光值(OD),取其平均值,扣除空白孔本底OD值,按下式计算实验组细胞增殖率(%):
NK细胞增殖率(%)=(实验组OD值-对照组OD值)/对照组OD值×100%,结果如表2所示:
表2 NK细胞增殖率测定结果
3.NK细胞对1301细胞杀伤率测定结果
以处于对数生长期的人急性T淋巴细胞白血病细胞1301为靶细胞,以实验组,对照组扩增的NK细胞作为效应细胞,采用CCK-8法检测NK细胞的杀伤活性。具体为10:1、25:1和50:1的效靶比将效应细胞和靶细胞混合,同时设置效应细胞孔,靶细胞孔,用酶标仪检测450 nm处的OD值。其中,杀伤率计算公式为:杀伤率=[1-(实验孔OD值-效应孔OD)/靶细胞孔OD值]×100%,在不同效靶比的情况下,实验组扩增的NK细胞对1301的杀伤活性均高于对照组扩增的NK细胞的杀伤活性,结果如表3所示:
表3细胞杀伤率测定结果
综上所述,利用本发明的NK细胞培养基及体外扩增NK细胞的方法,可促进NK细胞的体外增殖,又可显著提高其1301细胞的杀伤力。需要指出的是,本发明的NK细胞培养基为体外扩增NK细胞的无血清细胞培养基。
最后所应说明的是:以上实施例仅用以说明而非限制本发明的技术方案,尽管参照上述实施例对本发明进行了详细说明,本领域的普通技术人员应该理解:依然可以对本发明进行修改或者等同替换,而不脱离本发明的精神和范围的任何修改或局部替换,其均应涵盖在本发明的权利要求范围当中。
Claims (10)
1.一种体外高效扩增NK细胞的培养基,其特征在于,包括基础培养基和添加物,所述添加物各组分及浓度为:2.0-10.0%自体血浆,0.5-2.0 uM白藜芦醇,1.0-10.0 mM烟酰胺,1%丙酮酸钠,1%非必需氨基酸,1% L-谷氨酰胺。
2.根据权利要求1所述的NK细胞的培养基,其特征在于,所述基础培养基为X-VIVO 15培养基。
3.根据权利要求1所述的NK细胞的培养基,其特征在于,所述添加物及各组分浓度:2.0%-10.0%自体血浆,0.5-2.0 uM白藜芦醇,1.0-10.0 mM烟酰胺,1%丙酮酸钠,1% 非必需氨基酸,1% L-谷氨酰胺。
4.根据权利要求1所述的NK细胞培养基,其特征在于,所述添加物各组分及浓度为:10%自体血浆,1 uM白藜芦醇,5 mM烟酰胺,1%丙酮酸钠,1%非必需氨基酸,1% L-谷氨酰胺。
5.一种体外高效扩增NK细胞的方法,其特征在于,包括以下步骤:
培养瓶包被:1 mg/ml anti-HER2 MAb,用无菌7.6~8.2的无菌PBS梯度稀释抗体至所需浓度,包被T-75瓶,4 ℃过夜或37 ℃预包被1 h,最优浓度为10 ug/ml;
外周血采集:检测HBV抗原、抗HCV抗体、抗HIV抗体、抗梅毒螺旋体抗体,检测项目均为阴性;
单个核细胞分离;
接种:细胞以1~5×106/ml的密度接种到预先包被的T-75培养瓶中,加入20 ml NK细胞培养基,接种培养;
将步骤(3)获得的单个核细胞接种到培养容器中,从接种时间开始计时,每隔三天补加新鲜培养基,培养14天后收集细胞,所述培养基中含有权利要求4中的各种组分;
收集细胞进行质检和流式检测。
6.根据权利要求5所述的体外培养NK细胞的方法,其特征在于,初始悬于NK细胞培养基中NK细胞的密度为5×106个/20ml。
7.根据权利要求5所述的体外培养NK细胞的方法,其特征在于,所述自体血浆浓度为体积比10%,所述anti-HER2 MAb浓度为10 ug/ml,所述重组人IL-2的浓度为200 U/ml,所述重组人IL-15的浓度为1 ng/ml。
8.根据权利要求5所述的体外培养NK细胞的方法,其特征在于,所述基础培养基为X-VIVO 15培养基。
9.根据权利要求5所述的体外培养NK细胞的方法,其特征在于,所述添加物及各组分浓度为:2.0%-10.0%自体血浆,0.5-2.0 uM白藜芦醇,1.0-10.0 mM烟酰胺,1%丙酮酸钠,1% 非必需氨基酸,1% L-谷氨酰胺。
10.根据权利要求5所述,体外培养NK细胞的方法,其特征在于,所述细胞培养容器为细胞培养瓶或细胞培养袋。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010630415.2A CN113881629A (zh) | 2020-07-03 | 2020-07-03 | 一种体外高效扩增nk细胞的培养基及培养方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010630415.2A CN113881629A (zh) | 2020-07-03 | 2020-07-03 | 一种体外高效扩增nk细胞的培养基及培养方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113881629A true CN113881629A (zh) | 2022-01-04 |
Family
ID=79013041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010630415.2A Pending CN113881629A (zh) | 2020-07-03 | 2020-07-03 | 一种体外高效扩增nk细胞的培养基及培养方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113881629A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117551608A (zh) * | 2023-11-10 | 2024-02-13 | 深圳泽医细胞治疗集团有限公司 | 活化培养基、高分泌IFN-γ的NK细胞的培养方法及应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107119014A (zh) * | 2017-05-12 | 2017-09-01 | 青岛赛欧凯普图乐生物医药有限公司 | 一种nk细胞无动物源培养基 |
CN107326008A (zh) * | 2017-08-09 | 2017-11-07 | 上海莱馥医疗科技有限公司 | 一种从外周血中高效高纯度扩增自然杀伤细胞的方法 |
CN107460168A (zh) * | 2017-10-09 | 2017-12-12 | 天津长和生物技术有限公司 | 自然杀伤细胞培养基质及自然杀伤细胞的扩增培养方法 |
CN107574150A (zh) * | 2017-09-06 | 2018-01-12 | 万向东方生物科技有限公司 | 一种无血清免疫细胞培养基及其制备方法 |
CN107674860A (zh) * | 2017-07-14 | 2018-02-09 | 上海源培生物科技股份有限公司 | Nk92细胞无血清培养基 |
CN108220235A (zh) * | 2016-12-22 | 2018-06-29 | 细胞邦(北京)生物技术有限公司 | 一种体外活化扩增人自然杀伤(nk)细胞的方法及其专用培养体系 |
CN109294985A (zh) * | 2018-10-25 | 2019-02-01 | 江苏普瑞康生物医药科技有限公司 | 一种用于nk细胞体外扩增的培养基体系及nk细胞体外扩增的方法 |
CN109666639A (zh) * | 2018-12-24 | 2019-04-23 | 浙江大学 | 一种杀伤活性增强的nk细胞及其制备方法 |
-
2020
- 2020-07-03 CN CN202010630415.2A patent/CN113881629A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108220235A (zh) * | 2016-12-22 | 2018-06-29 | 细胞邦(北京)生物技术有限公司 | 一种体外活化扩增人自然杀伤(nk)细胞的方法及其专用培养体系 |
CN107119014A (zh) * | 2017-05-12 | 2017-09-01 | 青岛赛欧凯普图乐生物医药有限公司 | 一种nk细胞无动物源培养基 |
CN107674860A (zh) * | 2017-07-14 | 2018-02-09 | 上海源培生物科技股份有限公司 | Nk92细胞无血清培养基 |
CN107326008A (zh) * | 2017-08-09 | 2017-11-07 | 上海莱馥医疗科技有限公司 | 一种从外周血中高效高纯度扩增自然杀伤细胞的方法 |
CN107574150A (zh) * | 2017-09-06 | 2018-01-12 | 万向东方生物科技有限公司 | 一种无血清免疫细胞培养基及其制备方法 |
CN107460168A (zh) * | 2017-10-09 | 2017-12-12 | 天津长和生物技术有限公司 | 自然杀伤细胞培养基质及自然杀伤细胞的扩增培养方法 |
CN109294985A (zh) * | 2018-10-25 | 2019-02-01 | 江苏普瑞康生物医药科技有限公司 | 一种用于nk细胞体外扩增的培养基体系及nk细胞体外扩增的方法 |
CN109666639A (zh) * | 2018-12-24 | 2019-04-23 | 浙江大学 | 一种杀伤活性增强的nk细胞及其制备方法 |
Non-Patent Citations (5)
Title |
---|
LUCIA MALAGUARNERA: "Influence of Resveratrol on the Immune Response", 《NUTRIENTS》, vol. 11, no. 5, XP055774105, DOI: 10.3390/nu11050946 * |
QI LI等: "Concentration-Dependent Biphasic Effects of Resveratrol on Human Natural Killer Cells in Vitro", 《J.AGRIC.FOOD CHEM》, vol. 62 * |
应丹妮;陈焕芸;付岩;蔡海波;谭文松;: "谷氨酰胺和丙酮酸钠对NK-92细胞体外扩增的影响", 高校化学工程学报, no. 03 * |
陈玲;刘军权;周忠海;吕小婷;黄菲;李佚;陈复兴;: "白藜芦醇对人CIK细胞功能的影响", 中华全科医学, no. 10 * |
陈玲;陈复兴;刘军权;周忠海;吕小婷;朱云;张娟;: "白藜芦醇对人γδT细胞生长和杀伤功能的影响", 中草药, no. 10 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117551608A (zh) * | 2023-11-10 | 2024-02-13 | 深圳泽医细胞治疗集团有限公司 | 活化培养基、高分泌IFN-γ的NK细胞的培养方法及应用 |
CN117551608B (zh) * | 2023-11-10 | 2024-04-30 | 深圳泽医细胞治疗集团有限公司 | 活化培养基、高分泌IFN-γ的NK细胞的培养方法及应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107475192B (zh) | 一种以记忆干t细胞为主要成分的淋巴细胞群及其体外高效扩增方法 | |
CN104711225B (zh) | Nk细胞的体外制备方法 | |
Bauer et al. | Propagation of mouse mammary tumor cell lines and production of mouse mammary tumor virus in a serum-free medium | |
CN108588022B (zh) | 体外培养富集人cd4+和cd8+ tcm细胞的方法 | |
CN113151168B (zh) | 一种人nk细胞培养体系及制备方法 | |
CN109161527A (zh) | 一种高效的nk细胞扩增方法 | |
CN116333986A (zh) | 一种外泌体激活nk细胞的培养方法 | |
US20150197727A1 (en) | Method for obtaining monocytes or nk cells | |
CN115651903B (zh) | 高杀伤力的免疫细胞群及其培养方法、试剂组合物和应用 | |
CN112391344A (zh) | 一种无包被nk细胞体外扩增和培养方法 | |
CN111117958B (zh) | 一种人外周血调节性t细胞的体外扩增试剂盒及扩增方法 | |
CN112608896A (zh) | 一种nk细胞的培养方法及其应用 | |
CN115558641A (zh) | 高纯度效应免疫细胞群及其培养方法、试剂组合物和应用 | |
CN113881629A (zh) | 一种体外高效扩增nk细胞的培养基及培养方法 | |
CN107312751B (zh) | 一种诱导小鼠骨髓细胞稳定分化为未成熟树突状细胞的专用培养基及培养方法 | |
CN111172110B (zh) | 一种脐带血cik细胞的培养方法 | |
CN112251405A (zh) | 一种体外高效诱导扩增nk细胞的方法 | |
CN114075546A (zh) | 一种nk细胞扩增组合物及体外扩增培养方法 | |
CN110643573A (zh) | 一种链式nk细胞的培养方法 | |
CN110862962A (zh) | 一种没食子酸在体外培养扩增nk细胞的方法 | |
CN114438028B (zh) | 一种体外扩增外周血nk的方法 | |
CN115197909B (zh) | 一种nk细胞的体外培养方法 | |
CN113293130B (zh) | 一种肿瘤特异性t细胞的培养方法 | |
CN111154721B (zh) | Nk细胞扩增方法 | |
CN113564115A (zh) | 一种高扩增型dc-cik细胞及其制备和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220104 |
|
WD01 | Invention patent application deemed withdrawn after publication |